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The nephrotic syndrome is a clinical entity characterized
by proteinuria, hypoalbuminemia, edema and hyper-
lipidemia. All the features of this syndrome are ultimately
related to increased permeability of the glomerular capillary
to protein. A specific disease entity in its mildest form may
result in mild proteinuria insufficient to cause hypo-
albuminemia and the other physiological manifestations
of the nephrotic syndrome; the same disease in another
patient or at another time in the same patient may cause
marked proteinuria and the nephrotic state. The principal
difference between proteinuria alone and that associated
with the nephrotic syndrome in any specific disease would
therefore appear to be quantitative, although it is likely
that other factors play a role.
The glomerular capillary wall is composed of a fenestrated
endothelium, the glomerular basement membrane (GBM)
and the epithelial cell with foot processes that abut on the
GBM. It is through this structure that filtration and
selective impedance to the passage of protein occur (Fig. 1).
The permeability characteristics of the capillary result in
the virtual exclusion of proteins like albumin from the
glomerular filtrate but permit complete penetration by
smaller molecules such as inulin. The evidence that an
alteration in this capillary barrier is responsible for protein-
uria and the nephrotic syndrome includes the following
[reviewed in reference 1]: 1) histologic evidence of gb-
merular disease, deposition of immunoglobulin and
complement components along the glomerular capillaries
and fusion of the glomerular epithelial cell foot processes
have been regularly seen in various forms of glomerulo-
nephritis associated with proteinuria; 2) in certain forms
of experimental immune renal disease (e.g., antigen-
antibody complex disease and nephrotoxic nephritis) there
is clear evidence of glomerular capillary injury, which is
often associated with proteinuria and the nephrotic state;
3) in aminonucleoside of puromycin nephrosis in rats
morphologic studies have demonstrated fusion of the
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foot processes and decrease in colloidal iron and alcian
blue staining reactions of the epithelial glomerular poly-
anion [2, 3]. This negatively charged macromolecule has
been shown to be a siaboprotein that lines the epithelial
cell membrane and foot process [3—6]. Whether this
polyanion plays a role in the impermeability of the filter
or maintains the foot process architecture is unknown. In
this experimental form of nephrotic syndrome, increase
in the permeability of the glomerular capillary has been
demonstrated by micropuncture [7] as well as by ultra-
structural studies using marker proteins such as ferritin
or catalase [8—Il]. These latter studies suggest that the
permeability barrier resides in the GBM and the epithelial
slit pore; 4) physiologic studies in human renal disease
Fig. 1. Electron micrograph of the normal glomerular capillary
filter demonstrating the fenestrated endothelium (END), the
glomerular basement membrane (GBM) and the epithelial cell
(EP). The epithelial slit pores and membrane can be seen
between the foot processes of the epithelial cell (x 52,300).
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have provided indirect evidence that proteinuria is related
to altered glomerular permeability [12—14]. There is little
evidence to support alternative explanations for proteinuria
in nephrotic states, such as the possibility of decreased
tubular reabsorption of protein as a major factor.
It is difficult to develop a meaningful classification of
the various diseases that lead to the nephrotic syndrome,
since the precise pathogenetic mechanisms have not been
satisfactorily explained. Evidence that immunological
mechanisms play a role in the pathogenesis of some forms
of human nephrotic syndrome is derived from immuno-
pathologic studies, by analogy to certain diseases in
animals that are naturally occurring or induced by im-
munological manipulation, and by alterations in the levels
of serum complement and complement components. On
the basis of available evidence and considerable liberty,
the classification noted in Table 1 is suggested. No attempt
will be made to describe these diseases in detail.
mmunopatho1ogic studies
During the course of the last decade numerous studies
have demonstrated the regular occurrence of immune
reactants within the glomerulus in a variety of forms of
glomerulonephritis [15, 16]. The distribution and local-
ization of immunoglobulins and complement has been
useful in a number of instances in separating diseases into
various categories. These data are summarized in Table 2.
The recognition of an ultralinear immunofluorescent
pattern indicating the presence of immunoglobulin within
Table 1. Classification of the nephrotic syndrome
I. Immunologic glornerular capillary injury
A. Presumed antigen-antibody complex disease
Acute poststreptococcal glomerulonephritis
Lupus erythematosus
Chronic membranoproliferative glomerulonephritis
Glomerulonephritis associated with certain infections
Rapidly progressive glomerulonephritis
Membranous glomerulopathy (with or without renal vein
thrombosis)
Glomerulonephritis associated with certain malignancies
Glomerulonephritis associated with certain drugs (e. g.,
penicillamine)
B. AntiGBM antibody disease
Goodpasture's disease
Rapidly progressive glomerulonephritis
C. Unknown mechanism
Anaphylactoid purpura glomerulonephritis
II. Mechanism of glomerular capillary alteration unknown
A. Idiopathic nephrotic syndrome
1. With nil or minimal glomerular alteration
2. With mesangial proliferation
3. With glomerular sclerosis
B. Other causes
Congenital and familial nephrosis, amyloidosis, diabetic
nephropathy, chemicals (e. g., tridione and mercury),
sickle cell anemia, Hodgkin's disease, etc.
the GBM and the presence of antiGBM antibody has
been helpful in the diagnosis of Goodpasture's disease and
certain forms of rapidly progressive glomerulonephritts
[17, 18]. In our experience, this is a rare lesion. The immuno-
Table 2. Summary of immunopathologic observations and alterations in serum complement in various forms of nephrotic syndrome
Disease
CH50
Serum levels
of complement°
Glomerular deposits of immunoglobulins
and JJ1C by immunofluorescent microscopy
Cl C4 C2 C3 Distribution Pattern
I. Immunologic glomerulonephritis
Acute poststreptococcal R N or R N or R R R GBM, extra-GBM, mesangial Granular or nodular
Lupus erythematosus R R R R R GBM and mesangial Granular; linear
Membranoproliferative R N or R N or R N R GBM; infrequent mesangial Peripheral lobular
Nephritis with infection N or R (Rb) (Rb) (Rb) N or R GBM, mesangial Granular; focal
linear
Rapidly progressive N N GBM and mesangial; Granular
occasionally no deposits
Membranous N N GBM and epimembranous Granular or nodular
AntiGBM (Goodpasture's N N GBM Ultralinear
or Rapidly Progressive)
Anaphylactoid purpura N N Mesangial; rarely GBM Arborized; focal
linear
11. Idiopathic nephrotic N or R N or R N N N Negative or stalk and mesangial
syndrome
Congenital nephrotic N or R N Negative
syndrome
a Several low values obtained by hemolytic assay in one investigation [37].
b In one instance with shunt nephritis [41].
N— normal; R— reduced.
(Data derived from references 37, 41, 60—64, 68, 73—76.)
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fluorescent pattern frequently seen in diabetic nephropathy
may be indistinguishable from that of antiGBM antibody
disease [19, 20]. In diabetes, renal tissue from over 50%
of patients show this ultralinear distribution for IgG
usually associated with the presence of other proteins
such as albumin, fibrinogen and ceruloplasmin [20]. The
presence of these proteins, the inability to demonstrate
that eluted IgU fixes to GBM and the absence of in vitro
complement fixation strongly suggest that the proteins
are present on the basis of a nonimmunological mechanism.
These findings may reflect some intrinsic abnormality of
the GBM in diabetes. We have observed this distribution
of proteins in the GBM of children as early as two years
after onset of diabetes at a time when there were no
significant glomerular abnormalities by light microscopy.
Lesser quantities of IgG in an ultralinear distribution
similar to that described for Goodpasture's disease and
diabetic nephropathy may also be seen in the normal
kidney; in this circumstance it is quantitatively less intense
and usually associated with the presence of other proteins
such as albumin and fibrin. These immunofluorescent
findings probably reflect the presence of small quantities
of entrapped proteins within the GBM which we have
been able to detect by immunochemical techniques in
normal isolated GBM [21].
Patterns of immunofluorescence that are not of the
antiGBM variety are often described under a great number
of different and conflicting terms which mean different
things to different investigators. This confusion arises in
part because of the difficulty in defining precise location of
immune reactants within the glomerulus in some diseases.
The presence of discrete nodular deposits along the GBM
is a characteristic feature of antigen-antibody complex
disease because the appearance is similar to that observed
in experimentally induced serum sickness or chronic com-
plex disease (Figs. 2 and 3). In addition, there is often an
assumption that any variety of globulin deposition, which
is not characteristic of antiGBM disease, represents an
immune complex mechanism. This assumption is unwise,
as pointed out by McCluskey [16], since direct proof of an
immune complex pathogenesis would require demonstra-
tion that antibody in the glomerulus forms a complex
with a specific antigen —evidence which has been sub-
stantiated only in lupus erythematosus, where both antibody
[22—24] and antigen [24] have been demonstrated, possibly
in poststreptococcal glomerulonephritis [25—27] and certain
instances of glomerulonephritis associated with infection
[28—30] and malignancy [31]. No attempt will be made to
depict the various patterns of glomerular deposition of
immunoglobulin in various forms of glomerulonephritis
since these have been described in prior publications.
In some diseases, the immunoglobulin within glomerular
deposits reacts with certain antigens following elution with
solutions known to dissociate antigen-antibody complexes.
In Goodpasture's disease, the antibody has been shown
to have specificity for the GBM in vitro by immunopatho-
Fig. 2. Tissue from apatient with nephrotic syndrome and histologic
evidence of membranous glomerulopothy. The patient ultimately
developed DNA antibody and other evidences of lupus cry-
thematosus. Note the granular deposits of IgG along the GBM
demonstrated by immunofluorescent microscopy.
logic techniques and to react in vivo in monkeys causing
glomerulonephritis [18, 32]. Antibody eluted from kidney
of patients with lupus erythematosus reacts with nuclei,
desoxyribonucleoprotein and DNA (see Agnello, Koffler
and Kunkel, this issue).
Analogy to experimental forms of renal disease induced
by immunological manipulation
The analogy of certain experimental forms of immune
renal disease to human glomerulonephritis has been a
major factor in developing ideas regarding the pathogenesis
of human disease. The outstanding studies of Dixon and
his colleagues and many other workers have developed
the concepts of antigen-antibody complex disease and its
unique difference from antiGBM disease [33]. These
studies will not be reviewed here.
The change in the permeability barrier occurring after
immunologic insult (antigen-antibody complex nephritis
or antiGBM nephritis) is mediated by a variety of effector
mechanisms. The extensive studies of Cochrane and Henson
[34—36] have clearly demonstrated a major role for comple-
ment, leukocyte and platelets in the proteinuria of antiGBM
nephritis. The release of various mediators, cathepsins,
cationic proteins and other enzymes such as collagenases
from lysosomal granules probably plays a major role in
altering the filter, resulting in nonselective proteinuria
and the release of fragments of GBM into the urine. In
contrast, depletion of C3 by cobra venom factor or leuko-
cytes does not alter the glomerular histology or proteinuria
in acute experimental immune complex disease in rabbits,
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Fig. 3. Electron micrograph of a part of a glomerular capillary from the same patient described in Fig. 2, showing early morphologic changes
of membranous glomerulopathy. The larger figure demonstrates variable-sized densities accumulating primarily beneath the limiting
membrane of the epithelial cell and the GBM. Note that the epithelial surface of the GBM projects in "peglike" protrusion into the
epithelial cell in several loci. These protrusions are the silver-positive spikes seen by light microscopy. The insert demonstrates variable-
sized deposits of dense material in this same locus and emphasizes the probable sequence of development of such epithelial deposits.
EP— epithelial cell; END— endothelial cell; PMN— a partially degranulated polymorphonuclear leucocyte. (x 16,000; insert x 22,000).
so that the mechanism of altered glomerular capillary significant depression in the complement level has been
permeability in this disease remains unexplained, observed are outlined in Table 2. Gewurz et al [37] pointed
out important differences between the complement profile
in systemic lupus erythematosus and that seen in chronic
Studies on complement membranoproliferative glomerulonephritis associated with
During the last half-century, numerous studies have hypocomplementemia. In the former there was uniform
shown a reduced serum level of complement in acute post- depression of the earlier components in addition to C3t,
streptococcal glomerulonephritis. The diseases in which a whereas in the latter Cl, C4 and C2 were relatively normal
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when compared to a depression of C3t. On the basis of
this observation, the possibility was proposed that an
alternate system for complement activation might be
operative in this disease. An analogy was drawn between
the action of antigen-antibody complexes, on the one hand,
which result in depression of Cl, C4, C2 and C3t, compared
with the action of endotoxin or zymosan which activated
the terminal components (C3t).
Alternate complement pathway in glomerulonephritis.
Although it seems clear that immunological mechanisms
may be primary in the pathogenesis of many forms of
human glomerulonephritis and nephrotic syndrome, the
precise mechanism of this injury is unknown although it
appears to be mediated at least in part by the complement
system. The evidence that an alternate system for comple-
ment activation may be present includes the following:
1) studies carried out by Pillemer et al [38] nearly 20 years
ago elucidated a system in which properdin was character-
ized as a protein which in the presence of zymosan could
be removed from serum at 17° C, and participated in the
inactivation of C3 at 37° C. At least two other serum
factors were essential —factor A, a hydrazine-sensitive
factor, and factor B, a heat-labile factor. The precise
relevance of this system to human disease and its role as a
unique immunological system were challenged for a number
of reasons. A reduction in the activity of serum properdin
has been demonstrated in patients with acute poststrepto-
coccal nephritis and in certain instances of chronic gb-
merulonephritis [39]. We have demonstrated the presence
of properdin in the gbomerular deposits of all patients
with acute poststreptococcal glomerulonephritis and
chronic membranoproliferative glomerulonephritis with
hypocomplementemia [40, 41]. In other diseases (e.g.,
lupus erythematosus) deposits of properdin are less
frequently observed. 2) Gewurz et al [42] demonstrated
preferential fixation of the terminal six complement
components by gram negative bacterial endotoxin although
recent studies indicate that earlier components may be
necessary. Sandberg et al [43] and Oliveira et al [44] also
presented evidence for an alternate system by the demon-
stration of terminal complement component activation by
the F(ab) fragment of gunea pig yl and y2 and aggregated
gamma globulin. The yl antibody showed no interaction
with Cl, C4 and C2. This contrasted with the activity of y2
antibody, which activated the entire complement sequence
through the Fc fragment. 3) MUller-Eberhard and Götze
[45, 46] have recently presented evidence supporting the
existence of a second system for activating complement
essentially replacing the need for the first three components.
C3 proactivator (C3PA), a beta globulin, with a molecular
weight of 80,000 is cleaved into two fragments; the larger
one, which has gamma mobility on electrophoresis and a
molecular weight of 60,000, has been called C3 activator
since it is able to activate and split C3. Certain substances
including inulin, endotoxin, cobra venom factor and
immunoglobulin aggregates activate the system in the
presence of a 3S alpha globulin, C3PA convertase and an
activated hydrazine-sensitive factor which is related to C3.
C3PA and the glycine-rich beta-glycoprotein have been
shown to share antigenic determinants; factor B activity
has been described in both C3PA and the glycine-rich
beta-glycoprotein [47, 48]. There has been considerable
debate regarding the precise relationship between these
two molecules. In addition, the exact interaction between
properdin and the C3 proactivator system has not been
defined. 4) West et al [49] Spitzer et al [50] and Vallota et
al [51] have described a factor in the pseudoglobulin
fraction of serum from patients with chronic membrano-
proliferative glomerulonephritis the C3 nephritic factor
(C3NeF). This factor, in combination with a pseudogbobulin
cofactor and magnesium, forms C3 lytic nephritic factor
(C3LyNeF), which is able to cleave C3 to y2D and lilA.
C3PA, properdin and filA in renal disease. We have
attempted to evaluate the role of the alternate complement
system in various forms of glomerulonephritis by measure-
ment of serum levels of C3PA, properdin and $1 C. The
various methods of protein isolation, production of anti-
body, protein quantitation, and the specific studies sum-
marized here have been reported elsewhere [52]. The
serum concentration of fllA, properdin and C3PA were
carried out by modification of the immunodiffusion assay
described by Mancini in patients with chronic membrano-
proliferative glomerulonephritis (CMPGN), systemic lupus
erythematosus (SLE), acute poststreptococcal glomerul o-
nephritis (AGN) and other renal diseases. Evidence derived
from immunopathobogic studies and complement com-
ponent analysis has suggested that the alternate comple-
ment system may be involved, in part, in CMPGN [41].
Static values of properdin, C3PA and fllA represent a
number of different influences and may not reliably por-
tray the dynamic changes occurring in viva. It seems clear,
however, that significantly decreased values of properdin
are seen only when flIA is reduced—especially in AGN
but also in CMPGN (Fig. 4). In normal and SLE sera no
correlation was seen between levels of fllA and properdin—
in contradistinction to the positive correlation seen in sera
from patients with AGN, CMPGN and other renal diseases.
Just the opposite situation was observed when C3PA
data were evaluated: a positive correlation between levels
of fl1A and C3PA was observed in sera of normal and SLE
patients but not in AGN or CMPGN. In addition, the
levels of C3PA were most significantly reduced in hypo-
complementemic patients with SLE. Significant decreases
were also seen in hypocomplementemic AGN and CMPGN,
and normocomplementemic SLE and CMPGN. (Fig. 5).
The conclusion that C3PA appears to be more prom-
inently involved in SLE and properdin in AGN is perhaps
an oversimplification of a complex situation. Demon-
stration of a more cathodal electrophoretic migration of
properdin in some patients with CMPGN and SLE
emphasizes the limitations of static serum values in evalu-
ating any biologic system [52].
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Idiopathic nephrotic syndrome (INS)
This syndrome has certain unique characteristics that
separate it from other forms of nephrotic syndrome
associated with glomerulonephritis. These differences are
outlined in Table 3. The clinical and pathologic findings
have been described in detail in the excellent reviews of
White, Glasgow and Mills [53] and Habib and Kleinknecht
[54] and Churg, Habib and White [55].
The precise etiology of INS is unknown. Evidence that
immunological mechanisms play a role have been largely
circumstantial and have depended upon relationships to
certain events that imply an immunological mechanism,
iso namely, recurrent disease associated with respiratoryinfections, the rare association with exposure to toxins
such as bee stings, the occurrence of allergic manifestations
such as hay fever and pollen hypersensitivity with episodes
of the syndrome [56] and the response to cyclophosphamide
therapy which has been shown to prolong the duration of
remissions in children with frequently relapsing idiopathic
nephrotic syndrome [57—58].
Complement. Reduced serum levels of whole complement
activity have been detected in some patients with relapsing
Table 3. Comparison of various forms of immune-related gb-
merulonephritis and idiopathic nephrotic syndrome
Glomerulonephritis
Idiopathic
nephrotic
syndrome
Clinical features of
nephrotic syndrome
May be present.
Depends on amount
of proteinuria
Almost always
present
Frequency Major form of
nephrotic syndrome
in adults
Major form in
children
Light microscopy Proliferation and/or
gbomerular base-
ment membrane
(GBM) thickening
Normal or minimal
abnormalities;
mesangial proli-
feration
Immunofluorescent
microscopy
Prominent deposits
of immunoglobulin
and complement
(e. g., fl1C) along
the GBM and
mesangium
No GBM-oriented
deposits; gbomeruli
negative or show
focal stalk or
mesangial deposits
Electron
microscopy
Electron dense
deposits present;
GBM may be thick;
foot process fusion;
increased mesangial
matrix
Foot process fusion
Serum complement
(fllC or C3)
Normal or low Normal
Urine protein
selectivity
Normal or low High
Response to
prednisone
Only in lupus
erythematosus.
Complete in two to
four weeks in over
95% patients
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Fig. 4. Levels of properdin in patients with chronic membranopro-
liferative glomerulonephritis (CMPGN), systemic lupus erythe-
matosus (SLE), acute poststreptococcalglomerulonephritis (AGN)
and other renal diseases. There is a significant decrease in pro-
perdin (P< 0.01) only in patients with CMPGN and AGN with
reduced serum levels of fllA. (Data derived from [52].)
CMPGN SLE AGN Other
flA /15A J31A fl,A
<8383 >8383 >8383
--
..
-
Fig. 5. of C3PA in the same group ofpatients described in
Fig. 1. SLE and CMPGN groups with low or normal levels of
fllA and hypocomplementemic AGN had significantly reduced
values of C3PA. (Data derived from [52].)
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nephrotic syndrome [59]. However, this observation has
not been consistently confirmed and because of the associ-
ated biochemical changes induced by the nephrotic state,
measurements of whole complement activity are open to
question. Numerous studies have demonstrated normal
serum values for /31 C/fl1A as well as for C4 [60—64]. Lewis,
Carpenter and Schur [64] described a decrease in Clq in
one-third of patients with this disease, a finding that
likely reflects the metabolic effects of the nephrotic syn-
drome rather than an immune process.
Ngu, Barratt and Soothill [61] demonstrated a significant
increase in the titer of immunoconglutinin—autoantibody
to hidden antigenic determinants of C3 and C4— during
episodes of INS, even though the levels of whole comple-
ment and fl1C were essentially normal. The exact signifi-
cance of this observation is unknown, although elevations
in titer reflect immunological reactions and have been
observed in acute poststreptococcal glomerulonephritis
and viral infections.
C3FA, properdin and fl1C in INS. Measurements of
C3PA, properdin and fl1C in eight children with steroid-
responsive INS at the time of relapse when not receiving
corticosteroid therapy revealed the following values (mean
and range): /J1C—l8Omg/lOOml (154 to 219); C3PA—
24 jig N/mI (23 to 33); properdin 139 mg/l00 ml (92 to
198) (normal values, mean fl1C 165± 41 mg%;
C3PA 46± 12 jig N/ml; properdin 107± 17 mg%). The
values for /31 C and properdin are normal or slightly
elevated, whereas the levels of C3PA are significantly
depressed. The low values of C3PA may reflect urinary
loss, since the molecular weight is 80,000. In addition,
immunofluorescent studies of renal tissue using antiserum
to C3PA have not revealed significant glomerular fluores-
cence in any disease, although proximal tubules frequently
demonstrate this protein. Although it has been shown
that reduced serum values of flIC are not caused by
urinary loss, such may not be the situation with C3PA.
Immunopathologic studies. Immunopathologic studies
have been carried out on renal tissue from children with
INS and have demonstrated either no glomerular deposits
of IgG or fl1C or the presence of focal and local deposition
in the axial region and mesangial stalk [65]. Similar findings
have been observed by Habib and Kleinknecht [54], who
also observed the presence of 1gM in areas of focal sclerosis.
The recent demonstration of 1gB in glomeruli in the form
of "comma" deposits in patients with INS by Gerber and
Paronetta were especially interesting in view of the occa-
sional association with allergic states [66].
We have recently described immunopathologic studies
in INS using antisera against a number of different proteins
including 1gB [67]. The results of these studies, summarized
in Table 4, fail to demonstrate 1gB in the glomeruli of
19 patients with INS (Fig. 6). The reason for the differences
between these results and those of Gerber and Paronetta
are unknown, although it is possible that 1gB plays some
Table 4. Immunopathologic studies in idiopathic nephrotic
syndrome
Significantly positive glomerular
Morphologic
diagnosis
Steroid-
respon-
sivea
fluorescence using antisera to
IgG, IgA, 1gB, IgMC P1CC
fibrin, albumin,
properdin, C3PA
Minimal lesion 8/9 0/9 8/9 9/9
Mesangial
proliferation 3/3 0/3 3/3 3/3
Focal sclerosis 1/7 0/7 6/7 6/7
Normal controls 0/6 2/6 2/6
(Transplant donors)
a The demoninator indicates the total number of patients in
each group and the numerator denotes the number who ulti-
mately were shown to be steroid-responsive.
Three patients with minimal lesions and three with focal
sclerosis were receiving steroid therapy at the time of kidney
biopsy; the rest were untreated.
U The denominator indicates the number in each group evaluated
and the numerator the number with significantly positive
glomerular fluorescence.
c 1gM and flIC were focally present in the mesangial stalk; no
GBM-oriented deposits were present (modified from [67]).
role in atopic patients with nephrotic syndrome even
though it is not uniformly detected in glomeruli.
The presence of axial and mesangial deposits of 1gM
and fl1C in some glomeruli in a focal distribution cannot
be explained with certainty. The appearance of mesangial
deposits has been described late in the course of patients
with congenital nephrotic syndrome in whom tissue
obtained shortly after birth failed to reveal the presence
of immune deposits [68]. A similar finding has been
demonstrated in rats with aminonucleoside nephrosis, a
form of experimental nephrotic syndrome in which immune
mechanisms are not known to play a role [69]. In addition,
a unique relationship between mesangial function and
glomerular capillary permeability has been demonstrated
by Mauer et al [70] in aminonucleoside nephrosis in rats.
A five- to tenfold increase in the mesangial uptake of
intravenously administered aggregated IgG (I) has been
observed in animals with proteinuria. The reason for this
increased entrapment is unknown, although an important
interaction may exist between mesangial function and
events occurring at the filtering surface of the capillary.
We have also observed immunoglobulin and especially
/31 C in the glomerular stalk and afferent arterioles in
normal kidney tissue (e.g., transplant donor).
The regular absence of immunoglobulin, complement
components and electron dense deposits along the gb-
merular capillary filter make it unlikely that either an
antigen-antibody complex mechanism or antiGBM anti-
body is operative in INS. The failure to demonstrate
gbomerular-bound 1gB would place some question on the
role of reaginic antibody in all patients with INS.
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Fig. 6. Iminunopathologic studies on kidney tissue from patients with idiopathic nephrotic syndrome (INS). A) No evidence for
glomerular deposition of IgE in tissue from a patient with steroid-responsive nephrotic syndrome. A similar picture was seen utilizing
antisera to IgG, IgA, fibrin, albumin, properdin and C3PA. B) Focal deposition of 1gM is shown in this glomerulus from a child
with steroid-responsive INS. The exact locus cannot be determined with certainty, although the 1gM is probably present within the
mesangium.
A B
Fig. 7. A) Tissue from a patient with steroid-resistant nephrotic syndrome, demonstrating focal and local deposition of /31C in an area of
glomerular sclerosis. Note the negative staining glomerulus above. B) Electron micrograph of a segment of a glomerulus from a patient
with steroid-resistant nephrotic syndrome andfocal glomerular sclerosis. The epithelial cell (Ep) foot processes are fused along the normal-
appearing GBM. The mesangial matrix (mm) is increased in quantity and seen as GBM-like material between processes of the mesangial
cell (x 7500).
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The relationship between nil or minimal lesion nephrotic
syndrome and that associated with focal sclerosis is un-
known. Immunopathologic studies reveal little differences
between these two groups of patients with the exception
that areas of focal sclerosis are often associated with
nondescript deposition of immunoglobulins (Fig. 7).
Whether or not these syndromes represent two different
diseases or a variable expression of the same pathogenetic
process is unknown. Complete steroid responsiveness of
patients with minimal lesion compared with the virtual
steroid-resistance of patients with glomerular sclerosis
suggests at least some important biological differences. We
have recently had a unique opportunity to observe four
patients with steroid-resistant nephrotic syndrome associ-
ated with gradual glomerular sclerosis and ultimate renal
failure. All four were subjected to homotransplantation,
and recurrence of nephrotic syndrome has been documented
in three of these patients, suggesting that nonrenal factors
are important in the genesis of the disease [71].
It has not been possible to prove with certainty that
immunological mechanisms play no role in the pathogenesis
of INS. It seems clear, however, that attempts to identify
a specific immune mechanism analogous to antigen-
antibody complex disease or antiGBM nephritis have been
unsuccessful. It has been recognized for some time that
nephrotic syndrome may occur in association with Hodg-
kin's disease. There is no evidence, in most instances,
that this represents an antigen-antibody complex disease
as postulated for the renal disease associated with other
malignancies [31]. There is good evidence, however, on
the basis of light, fluorescent and electron microscopy,
that the renal disease is similar to or the same as INS
[72]. This provocative observation may indicate that a
lymphoreticular cellular mechanism may in some way
play a role in glomerular permeability to protein.
Summary
Available evidence suggests that the nephrotic syndrome
is caused by increased permeability of the glomerular
capillary filter to protein. This evidence is derived from
morphologic and immunopathologic studies in human
and experimental renal disease and from micropuncture
and electron microscopic studies using enzyme markers.
Evidence that immunological mechanisms play a major
role in certain forms of nephrotic syndrome are derived
from immunopathologic observations, by analogy to
certain forms of experimental renal disease and by altera-
tions in serum complement and complement component
levels. This group of diseases includes a variety of forms
of glomerulonephritis which are presumed to be antigen-
antibody-complex—mediated as well as the less frequent
forms of antiGBM nephritis. Evidence that the alternate
complement system may be involved in certain forms of
immune-related glomerulonephritis includes the demonstra-
tion of properdin and C3 in the glomerular deposits of all
patients with membranoproliferative glomerulonephritis
and acute poststreptococcal nephritis, the demonstration
of a decrease in the level of properdin in both of these
diseases associated with a reduction of levels of serum lilA,
the demonstration of a positive correlation between levels
of /IIA and C3PA in SLE patients associated with a
significant depression in the level of C3PA and a demonstra-
tion of a more cathodal electrophoretic migration of
properdin in some patients with chronic membrano-
proliferative glomerulonephritis and lupus erythematosus.
Evidences that immunological mechanisms play a role
in idiopathic nephrotic syndrome have been largely circum-
stantial and include the frequent recurrence of the disease
associated with respiratory infection, the infrequent
association with certain toxins and hypersensitivity states,
the response to cyclophosphamide therapy and the demon-
stration of increase in the serum level of immunoconglutinin.
Serum levels of complement and lilA have generally been
within normal limits. Immunopathologic studies have
generally revealed either the absence of significant immune
deposits or the presence of stalk or mesangial deposits of
1gM or PlC; it is possible that this is a consequence of
proteinuria and not a cause of it, although the matter has
not been settled. We have found no evidence for IgE
within the glomeruli of patients with this syndrome.
Measurement of alternate complement pathway compo-
nents has revealed a significant decrease in the level of
C3PA—which may be due to urinary loss of this protein
although this has not been proved. There is thus no con-
clusive proof that this form of nephrotic syndrome is
immunologically mediated.
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